MAGEC1 and Miyoshi myopathy: In addition, specific antibodies against MAGE-C1 were detected in 50% of MM patients and in nearly all patients with MAGE-C1 expressing myeloma cells, demonstrating a high immunogenicity of epitopes derived from MAGE-C1 [32].